Related Experiment Video
Updated: Aug 10, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
[Gene therapy for relapsed breast cancer]
Shunji Takahashi1, Yoshikazu Sugimoto
1Department of Clinical Chemotherapy and Gene Therapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 15, 2006
Summary
Multidrug resistance (MDR1) gene therapy shows promise for advanced breast cancer. Clinical trials indicate successful in vivo enrichment of MDR1-transduced cells with docetaxel, with no apparent adverse effects observed.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Context:
- Advanced breast cancer presents significant treatment challenges.
- Current therapeutic strategies include oncogene suppression, immunotherapy, suicide gene transfer, and drug resistance gene transfer.
- Multidrug resistance (MDR1) gene therapy is an emerging approach.
Purpose:
- To evaluate the safety and efficacy of multidrug resistance (MDR1) gene therapy in patients with advanced breast cancer.
- To assess the in vivo enrichment of MDR1-transduced hematopoietic stem cells following high-dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT).
Summary:
- A clinical study involving MDR1 gene therapy was initiated for advanced breast cancer patients.
- Patients underwent high-dose chemotherapy, PBSCT with MDR1-transduced cells, and subsequent docetaxel treatment.
- In vivo enrichment of MDR1-transduced cells was observed during docetaxel treatment in three treated patients.
- No apparent adverse effects were associated with the MDR1 gene transfer procedure.
Impact:
- MDR1 gene therapy demonstrates potential for enhancing treatment outcomes in advanced breast cancer.
- The findings support the feasibility of using gene therapy to improve chemotherapy efficacy and reduce bone marrow toxicity.
- This approach may offer a new therapeutic avenue for overcoming drug resistance in cancer treatment.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
07:45Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.